Free Trial
NASDAQ:ANNX

Annexon Q4 2024 Earnings Results & Report

Annexon logo
$4.21 -0.02 (-0.47%)
Closing price 11/10/2026 04:00 PM Eastern
Extended Trading
$4.26 +0.05 (+1.19%)
As of 08:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon missed analyst earnings expectations in its Q4 2024 results, released March 3, 2025. The company reported EPS of -$0.33 versus the -$0.28 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Annexon EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Annexon Q4 2024 Earnings FAQ

Annexon (NASDAQ:ANNX) reported earnings of -$0.33 per share for Q4 2024, missing the consensus estimate of -$0.28. The report was announced on Monday, March 3, 2025.

Annexon Earnings Headlines

Annexon (ANNX) Projected to Announce Earnings on Monday
Inside Nevada's 60 Million Ounce Gold Corridor
Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold. Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program. With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district.tc pixel
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively.

Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye. Annexon’s candidates remain in development and are not approved medicines.

Founded in 2011, Annexon is headquartered in Brisbane, California. The company conducts clinical development and research to advance its antibody therapies.

View Annexon Profile